Key clinical point: Fingolimod at a 0.5-mg dose had superior efficacy compared with glatiramer acetate in reducing disease activity in patients with relapsing-remitting multiple sclerosis.
Major finding: Annualized relapse rate was 0.153 for fingolimod 0.5 mg, versus 0.258 for glatiramer acetate (40.7% relative reduction; P = .013).
Study details: A randomized, three-armed, phase 3b study (ASSESS) enrolling 1,054 patients with relapsing-remitting multiple sclerosis.
Disclosures: Novartis sponsored the study. Dr. Cree provided disclosures related to Abbvie, Akili, Biogen, EMD Serono, GeNeuro, and Novartis.
Cree B et al. AAN 2019, Abstract 56.009.